In DAPA-HF (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure), the reduction in worsening HF events, defined as either an unplanned hospitalization or an urgent visit requiring intravenous therapy for HF, was seen as early as the first few weeks.4 The mechanism for this is unclear, but one possible hypothesis is the diuretic effect of SGLT2 inhibition.5–8. This evidence concerns the gene SLC5A2 and heart failure.